ACM
ACET icon

Aquilo Capital Management’s Adicet Bio ACET Stock Holding History

Aquilo Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-153,512
Closed -$1.85M – 1
2025
Q1 		$1.85M Sell
153,512
-4,688
-3% -$67K 3.32% 9
2024
Q4 		$2.44M Hold
158,200
– – 3.67% 11
2024
Q3 		$3.64M Hold
158,200
– – 2.76% 11
2024
Q2 		$3.06M Buy
+158,200
New +$4.24M 2.95% 11

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Aquilo Capital Management's ACET Position: Q2 2025 in Review

Aquilo Capital Management sold out of Adicet Bio (ACET) in Q2 2025, closing a stake of 153,512 shares — an estimated $1.85M sold.

Aquilo Capital Management first reported a position in ACET in Q2 2024 and held it in 4 quarters. The position peaked at $3.64M in Q3 2024. 49 funds tracked by Wall St. Rank hold ACET as of Q2 2025.

  • Aquilo Capital Management reported no remaining Adicet Bio position as of Q2 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 153,512 Adicet Bio shares in Q2 2025, an estimated $1.85M.
  • Aquilo Capital Management first reported a position in Adicet Bio in Q2 2024 and held it in 4 quarters.
  • Aquilo Capital Management's Adicet Bio position peaked at $3.64M in Q3 2024.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2025.

Based on Aquilo Capital Management's 13F filing for Q2 2025.